Nektar Therapeutics (NKTR):企業の財務・戦略的SWOT分析

◆英語タイトル:Nektar Therapeutics (NKTR) - Financial and Strategic SWOT Analysis Review
◆商品コード:GDPH4344FSA
◆発行会社(調査会社):GlobalData
◆発行日:2021年3月
◆ページ数:56
◆レポート言語:英語
◆レポート形式:PDF
◆納品方法:Eメール
◆対象地域:アメリカ
◆産業分野:Pharmaceuticals and Healthcare
◆販売価格オプション(消費税別)
Site License(同一事業所内共有可)USD250 ⇒換算¥37,000見積依頼/購入/質問フォーム
Enterprisewide License(複数事業所内共有可)USD375 ⇒換算¥55,500見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日〜2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送しますので、請求書発行日より2ヶ月以内に振込をお願いします。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はGlobalData社の日本における正規販売代理店です。同社発行の企業調査レポートに関するお問い合わせは弊社までお願い致します。
GlobalData社の概要はこちらでご確認いただけます。



【レポートの概要】

Nektar Therapeutics (NKTR) – Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and the potential opportunities and threats. The profile helps you formulate strategies that augment your business by enabling you to understand your partners, customers and competitors better.
The profile contains critical company information including:

- Business description – A detailed description of the company’s operations and business divisions.
- Corporate strategy – Analyst’s summarization of the company’s business strategy.
- SWOT Analysis – A detailed analysis of the company’s strengths, weakness, opportunities and threats.
- Company history – Progression of key events associated with the company.
- Major products and services – A list of major products, services and brands of the company.
- Key competitors – A list of key competitors to the company.
- Key employees – A list of the key executives of the company.
- Executive biographies – A brief summary of the executives’ employment history.
- Key operational heads – A list of personnel heading key departments/functions.
- Important locations and subsidiaries – A list and contact details of key locations and subsidiaries of the company.
- Detailed financial ratios for the past five years – The latest financial ratios derived from the annual financial statements published by the company with 5 years history.
- Interim ratios for the last five interim periods – The latest financial ratios derived from the quarterly/semi-annual financial statements published by the company for 5 interims history.

Highlights

Nektar Therapeutics (Nektar) discovers and develops novel therapeutic drug candidates based on its PEGylation and advanced polymer conjugate technology platforms to address unmet medical needs. The company’s technology platforms offer a wide range of functional attributes, which optimizes and enhances the profile of wide range of molecules including wide classes of drugs targeting numerous disease areas. The company’s products focus on various therapeutic areas, including, cancer, pain, infections and immunology among others. Its research and development activities involve peptides, proteins, antibodies, small molecule drugs and other potential biologic drug candidates. Nektar Therapeutics is headquartered in San Francisco, California, the US.

Nektar Therapeutics Key Recent Developments

Feb 26,2021: Nektar Therapeutics reports fourth quarter and year-end 2020 financial results
Feb 18,2021: Nektar to Announce Financial Results for the Fourth Quarter and Year-Ended 2020 on Thursday, February 25, 2021
Jan 05,2021: Nektar appoints Dr. Brian Kotzin as interim chief medical officer and head of development
Nov 05,2020: Nektar Therapeutics reports third quarter 2020 financial results
Sep 28,2020: Nektar Therapeutics : Departure of Directors

Key benefits of buying this profile include:

You get detailed information about the company and its operations to identify potential customers and suppliers.
- The profile analyzes the company’s business structure, operations, major products and services, prospects, locations and subsidiaries, key executives and their biographies and key competitors.

Understand and respond to your competitors’ business structure and strategies, and capitalize on their weaknesses. Stay up to date on the major developments affecting the company.
- The company’s core strengths and weaknesses and areas of development or decline are analyzed and presented in the profile objectively. Recent developments in the company covered in the profile help you track important events.

Equip yourself with information that enables you to sharpen your strategies and transform your operations profitably.
- Opportunities that the company can explore and exploit are sized up and its growth potential assessed in the profile. Competitive and/or technological threats are highlighted.

Scout for potential investments and acquisition targets, with detailed insight into the companies’ strategic, financial and operational performance.
- Financial ratio presented for major public companies in the profile include the revenue trends, profitability, growth, margins and returns, liquidity and leverage, financial position and efficiency ratios.

Gain key insights into the company for academic or business research.
- Key elements such as SWOT analysis, corporate strategy and financial ratios and charts are incorporated in the profile to assist your academic or business research needs.

Note: Some sections may be missing if data is unavailable for the company

【レポートの目次】

Table of Contents
List of Tables
List of Figures
Section 1 – About the Company
Nektar Therapeutics – Key Facts
Nektar Therapeutics – Key Employees
Nektar Therapeutics – Key Employee Biographies
Nektar Therapeutics – Major Products and Services
Nektar Therapeutics – History
Nektar Therapeutics – Company Statement
Nektar Therapeutics – Locations And Subsidiaries
Head Office
Other Locations & Subsidiaries
Section 2 – Company Analysis
Company Overview
Nektar Therapeutics – Business Description
Geographical Segment: Rest of World
Performance
Geographical Segment: United States
Performance
Nektar Therapeutics – Corporate Strategy
Nektar Therapeutics – SWOT Analysis
SWOT Analysis – Overview
Nektar Therapeutics – Strengths
Nektar Therapeutics – Weaknesses
Nektar Therapeutics – Opportunities
Nektar Therapeutics – Threats
Nektar Therapeutics – Key Competitors
Section 3 – Company Financial Ratios
Financial Ratios – Capital Market Ratios
Financial Ratios – Annual Ratios
Performance Chart
Financial Performance
Financial Ratios – Interim Ratios
Financial Ratios – Ratio Charts
Section 4 – Company’s Lifesciences Financial Deals and Alliances
Nektar Therapeutics, Pharmaceuticals & Healthcare, Deals By Year, 2015 to YTD 2021
Nektar Therapeutics, Pharmaceuticals & Healthcare, Deals By Type, 2015 to YTD 2021
Nektar Therapeutics, Recent Deals Summary
Section 5 – Company’s Recent Developments
Feb 26, 2021: Nektar Therapeutics reports fourth quarter and year-end 2020 financial results
Feb 18, 2021: Nektar to Announce Financial Results for the Fourth Quarter and Year-Ended 2020 on Thursday, February 25, 2021
Jan 05, 2021: Nektar appoints Dr. Brian Kotzin as interim chief medical officer and head of development
Nov 05, 2020: Nektar Therapeutics reports third quarter 2020 financial results
Sep 28, 2020: Nektar Therapeutics : Departure of Directors
Aug 06, 2020: Nektar Therapeutics reports second quarter 2020 financial results
May 07, 2020: Nektar Therapeutics reports first quarter 2020 financial results
May 07, 2020: Nektar to Announce Financial Results for the First Quarter 2020 on Thursday, May 7, 2020, After Close of U.S.-Based Financial Markets
Feb 27, 2020: Nektar Therapeutics reports fourth quarter and year-end 2019 financial results
Feb 27, 2020: Nektar to Announce Financial Results for the Fourth Quarter and Year-Ended 2019 on Thursday, February 27, 2020, After Close of U.S.-Based Financial Markets
Section 6 – Appendix
Methodology
Ratio Definitions
About GlobalData
Contact Us
Disclaimer

List of Tables
Nektar Therapeutics, Key Facts
Nektar Therapeutics, Key Employees
Nektar Therapeutics, Key Employee Biographies
Nektar Therapeutics, Major Products and Services
Nektar Therapeutics, History
Nektar Therapeutics, Other Locations
Nektar Therapeutics, Subsidiaries
Nektar Therapeutics, Key Competitors
Nektar Therapeutics, Ratios based on current share price
Nektar Therapeutics, Annual Ratios
Nektar Therapeutics, Annual Ratios (Cont...1)
Nektar Therapeutics, Annual Ratios (Cont...2)
Nektar Therapeutics, Interim Ratios
Nektar Therapeutics, Pharmaceuticals & Healthcare, Deals By Year, 2015 to YTD 2021
Nektar Therapeutics, Pharmaceuticals & Healthcare, Deals By Type, 2015 to YTD 2021
Nektar Therapeutics, Recent Deals Summary
Currency Codes
Capital Market Ratios
Equity Ratios
Profitability Ratios
Cost Ratios
Liquidity Ratios
Leverage Ratios
Efficiency Ratios

★海外企業調査レポート[Nektar Therapeutics (NKTR):企業の財務・戦略的SWOT分析]についてメールでお問い合わせはこちら

■おすすめ企業レポート■
  • GridPoint, Inc.:電力:M&Aディール及び事業提携情報
    Summary GridPoint, Inc. (GridPoint), a subsidiary of Twenty First Century Utilities LLC, is a smart buildings technology company. It provides visibility into facility operations, and assists customers to automate and control sites, lower energy spend, and manage day-to-day operations. The company pr …
  • Duke Realty Corporation:企業の戦略・SWOT・財務情報
    Duke Realty Corporation - Strategy, SWOT and Corporate Finance Report Summary Duke Realty Corporation - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service off …
  • Astellas Pharma Europe Ltd-製薬・医療分野:企業M&A・提携分析
    Summary Astellas Pharma Europe Ltd (Astellas Pharma), a subsidiary of Astellas Pharma Inc is a manufacturer and distributor of drug products. The company provides pharmaceutical drugs in the areas of oncology, transplantation, urology, anti-infective, pain management and dermatology. It also provide …
  • Sun Hydraulics Corporation:企業の戦略・SWOT・財務情報
    Sun Hydraulics Corporation - Strategy, SWOT and Corporate Finance Report Summary Sun Hydraulics Corporation - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and servi …
  • FLIR Systems Inc:企業の戦略・SWOT・財務情報
    FLIR Systems Inc - Strategy, SWOT and Corporate Finance Report Summary FLIR Systems Inc - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and cor …
  • Xiwang Sugar Holdings Co Limited:企業の戦略・SWOT・財務情報
    Xiwang Sugar Holdings Co Limited - Strategy, SWOT and Corporate Finance Report Summary Xiwang Sugar Holdings Co Limited - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, produ …
  • Wilmar International Ltd (F34):企業の財務・戦略的SWOT分析
    Wilmar International Ltd (F34) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weakn …
  • ASX Ltd (ASX):企業の財務・戦略的SWOT分析
    ASX Ltd (ASX) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and the pot …
  • HiberGene Diagnostics Ltd:医療機器:M&Aディール及び事業提携情報
    Summary HiberGene Diagnostics Ltd (HiberGene Diagnostics) is a medical equipment company that manufactures, develops and markets molecular diagnostic tests for human infectious diseases using the LAMP technology. The company’s products include HG C. Difficile, HG Meningococcus, HG Group B Streptococ …
  • TRACOE medical GmbH:企業の戦略的SWOT分析
    TRACOE medical GmbH - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major products and se …
  • Chemed Corp (CHE):企業の財務・戦略的SWOT分析
    Summary Chemed Corp (Chemed) is a diversified company. The company operates through its segments including Vitas and Roto-Rooter. Its Vitas segment provides end-of-life hospice care for heart disease, stroke, multiple sclerosis, lung disease, liver disease, and kidney diseases, among others. Chemed …
  • Interprotein Corp:製薬・医療:M&Aディール及び事業提携情報
    Summary Interprotein Corp (Interprotein) is a drug development company that develops active modulators for protein-protein interaction (PPI) targets. The company offers products such as IL-6 inhibitor, IgE inhibitor, notch1 inhibitor, tubulin polymerization inhibitors, TIM-3 inhibitor, NKG2A, HLA-E …
  • NicozDiamond Insurance Limited:企業の戦略・SWOT・財務情報
    NicozDiamond Insurance Limited - Strategy, SWOT and Corporate Finance Report Summary NicozDiamond Insurance Limited - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product a …
  • Arise AB (ARISE):企業の財務・戦略的SWOT分析
    Arise AB (ARISE) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and the …
  • Aboitiz Power Corporation (AP):電力:M&Aディール及び事業提携情報
    Summary Aboitiz Power Corporation (Aboitiz Power) a subsidiary of Aboitiz Equity Ventures Inc is a holding company that operates privately-owned generation companies and distribution utilities. Its power generation portfolio sources include hydropower, geothermal, coal, and oil. The company sells it …
  • Mace Group Ltd:企業の戦略・SWOT・財務情報
    Mace Group Ltd - Strategy, SWOT and Corporate Finance Report Summary Mace Group Ltd - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and corpora …
  • Titan Machinery Inc (TITN):企業の財務・戦略的SWOT分析
    Titan Machinery Inc (TITN) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesse …
  • Castle View International Holdings Limited:企業の戦略・SWOT・財務情報
    Castle View International Holdings Limited - Strategy, SWOT and Corporate Finance Report Summary Castle View International Holdings Limited - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, …
  • Indian Oil Corporation Limited:企業の戦略・SWOT・財務情報
    Indian Oil Corporation Limited - Strategy, SWOT and Corporate Finance Report Summary Indian Oil Corporation Limited - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product a …
  • Simulations Plus Inc (SLP):企業の財務・戦略的SWOT分析
    Simulations Plus Inc (SLP) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesse …

◆H&Iグローバルリサーチ株式会社のお客様(例)◆